< p > <大胆>背景:< /大胆>胃食管反流病(GERD)和功能性消化不良(FD)是在普通人群中很常见。在孕妇GERD患病率相当高,它增加在年轻的时候,和肥胖。粘膜保护剂(海洋保护区)场外交易(OTC)治疗FD和GERD通常单独使用或作为添加治疗质子泵抑制剂(ppi)。现实世界的数据通过调查允许销售产品的临床评价,也符合新规定substance-based医疗设备(SBMDs)。< / p > < p > <大胆>目的:< /大胆>研究旨在评估感知的有效性、安全性、和模式使用的患者,医生,和药剂师的自然MPA Poliprotect评估验证调查方法。Methods: Questionnaire repeatability was first assessed, resulting in the intraclass correlation coefficient agreement level >0.9 in the three validation cohorts of physicians, pharmacists, and patients. All questions were closed multiple-choice, allowing measuring variations in frequency, quality, or magnitude of effect on a 5-point Likert-like verbal scale.
Results: Three different surveys were performed in Italy and Spain on a total of 3,471 physicians, including 77 gastroenterologists, 848 patients, and 146 pharmacists who had an experience with Poliprotect in the previous year. Over 90% of general practitioners (GPs) rated Poliprotect effectiveness as good/excellent in controlling pyrosis, 80% for epigastric pain, and approximately 70% for digestion difficulties. GPs reported Poliprotect as very or extremely useful as an alternative to PPIs (73%) and for pregnancy-associated GERD symptoms (61%), almost unanimously (99.5%) reporting an excellent to good tolerability; 79% of the gastroenterologists answered to be extremely or very satisfied with the improvement of typical GERD symptoms, whereas improvement of dyspepsia and pregnancy- and breast-feeding-associated GERD symptoms was rated as highly satisfactory for 69, 52, and 62%, respectively, among GI specialists. Its use because of painful dyspeptic symptoms was reported by over 80% of patients, who rated symptom relief as excellent/good, and reported a marked quality-of-life improvement in 73% and in 65% of their answers, respectively. The product was used as monotherapy by 63% of patients. Conclusion: Large-scale, validated surveys support the safety and effectiveness of Poliprotect in the treatment of common functional upper GI disorders.